https://www.selleckchem.com/pr....oducts/brigatinib-ap
We assessed CUD symptoms via interviews at pre-treatment and four-month follow-up. Significant, durable reductions in DI and all cannabis use outcomes occurred in both conditions. Compared to the HVC condition, the DTI led to greater reductions in use frequency during the treatment period. Reductions in self-reported DI were correlated with reductions in coping motives and CUD symptoms. The DTI's impact on all outcomes was largely comparable to the control condition, though it may have utility as an adjunctive intervention. T
Like
Comment
Share
